Human Longevity, Inc. Receives CLIA Certification

(SAN DIEGO, CA) April 28, 2015 – Human Longevity, Inc. (HLI), the genomic-driven health information technology company, today announced that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human Services’ (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license.

Continue Reading →

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples

(LA JOLLA, CA) January 14, 2015—Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced a multi-year agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. HLI, using proprietary tools and unique expertise, will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.

Continue Reading →

Human Longevity, Inc. Signs Collaborative Agreement with King’s College London to Access TwinsUK Registry

HLI Team and Professor Tim Spector, M.D., to Collaborate Using this Unique Registry of more than 11,000 well-Characterized Twins

(LA JOLLA, CA) November 13, 2014—Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, today announced a collaborative agreement with King’s College London to access their TwinsUK Registry.

Continue Reading →

Human Longevity, Inc. Hires Industry Experts Barry Merriman, Ph.D., and Paul Mola, M.S. to Lead New Global Solutions Initiative

(LA JOLLA, CA) October 31, 2014—Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, today announced the addition of Barry Merriman, Ph.D., as Vice President of Global Technology Assessment and Paul Mola, M.S. as Head of Global Solutions. The two will work together in HLI’s new Global Solutions Initiative to seek strategic business opportunities worldwide.

Continue Reading →

Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications

Celgene Makes Equity Investment in HLI

(LA JOLLA, CA) August 11, 2014—Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today announced it has signed an agreement with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene’s proprietary placental cell population, PSC-100.

Continue Reading →

Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist

(LA JOLLA, CA) July 29, 2014—Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today announced they have hired Franz Och, Ph.D., an expert in machine learning and machine translation as the company’s Chief Data Scientist. Och comes to HLI from Google where he was Distinguished Research Scientist and the Head of Google Translate. He will report directly to HLI Co-Founder and CEO, J. Craig Venter, Ph.D.

Continue Reading →

Page 3 of 4 1234